Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Reports Increased Fiscal Q4 Losses on Higher Expenses


Arrowhead Research this week reported its fiscal fourth-quarter financial results, posting a higher net loss amid increased operating expenses.

The company also said that efforts to integrate its subsidiaries into a single company are underway.

According to Arrowhead, its net loss for the three-month period ended Sept. 30 was $2.8 million, or $0.39 a share, versus a loss of $2 million, or $0.28 per share, in the same period a year before.

Arrowhead recorded revenues of $296,000 in the quarter, versus no revenues a year earlier. However, the company's fourth-quarter operating costs jumped to $2.9 million from $1.8 million last year.

In a statement, Arrowhead President and CEO Christopher Anzalone said that the company is “well underway [toward] integrating our subsidiaries and programs into one cohesive operating company with multiple products and technologies.”

Arrowhead has maintained a strong interest in RNAi through its Calando Pharmaceuticals subsidiary, and it recently acquired the US RNA therapeutic assets of Roche (GSN 10/27/2011). The company also holds a stake in nanomedicines firm Leonardo Biosystems, which has developed a delivery technology with potential in RNAi (GSN 5/20/2010).